| Today’s Big NewsMar 20, 2024 |
| By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
|
|
|
By Gabrielle Masson A new immuno-oncology biotech has emerged, clasping $150 million that will go toward developing next-gen T cell engagers (TCEs) targeting a range of hard-to-treat tumors. |
By Max Bayer Acelyrin's subcutaneous thyroid eye disease treatment posted proof-of-concept data that were similar to Amgen's Tepezza. The readout is the latest in a wave of data that's fortified the biotech's 2024 comeback effort. |
By Gabrielle Masson Eli Lilly believes community-based clinical trials are the wave of the future and is pushing sponsors to embrace the paradigm as a way to boost enrollment and diversity. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Fraiser Kansteiner After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too. |
By Kevin Dunleavy When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. Sales came to 1.5 billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1 billion) for 2023, coming up short of expectations. |
By Zoey Becker Madrigal's Rezdiffra became the first drug approved to treat metabolic dysfunction-associated steatohepatitis just a few days ago. Now, the company looks to support the upcoming launch by selling shares. |
By Noah Tong Accountable care organizations are largely supportive of CMS' new primary care model released Tuesday, they wish the agency would broaden its scope to include all ACOs. |
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
Fierce podcasts Don’t miss an episode |
| In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
|
|---|
|
|
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
